Q1 EPS Estimate for iTeos Therapeutics Boosted by Analyst

iTeos Therapeutics, Inc. (NASDAQ:ITOS) – Analysts at HC Wainwright boosted their Q1 2025 earnings estimates for shares of iTeos Therapeutics in a report issued on Thursday, March 6th. HC Wainwright analyst S. Ramakanth now expects that the company will earn ($1.39) per share for the quarter, up from their previous estimate of ($1.44). HC Wainwright currently has a “Buy” rating and a $46.00 target price on the stock. The consensus estimate for iTeos Therapeutics’ current full-year earnings is ($3.49) per share. HC Wainwright also issued estimates for iTeos Therapeutics’ Q2 2025 earnings at ($1.44) EPS, Q3 2025 earnings at ($1.48) EPS, Q4 2025 earnings at ($1.53) EPS, FY2026 earnings at ($5.68) EPS, FY2027 earnings at ($3.46) EPS and FY2028 earnings at ($0.74) EPS.

Other equities analysts have also recently issued research reports about the company. Wells Fargo & Company dropped their price target on iTeos Therapeutics from $19.00 to $17.00 and set an “overweight” rating on the stock in a research report on Thursday. JPMorgan Chase & Co. lowered their price target on shares of iTeos Therapeutics from $22.00 to $15.00 and set an “overweight” rating on the stock in a research note on Thursday. Finally, Wedbush reaffirmed an “outperform” rating and issued a $25.00 price objective on shares of iTeos Therapeutics in a research note on Wednesday, March 5th.

iTeos Therapeutics Price Performance

Shares of iTeos Therapeutics stock opened at $7.05 on Monday. The stock has a market capitalization of $257.56 million, a price-to-earnings ratio of -2.24 and a beta of 1.38. iTeos Therapeutics has a 12 month low of $6.67 and a 12 month high of $18.75. The firm’s fifty day simple moving average is $7.52 and its 200-day simple moving average is $9.36.

iTeos Therapeutics (NASDAQ:ITOS) last posted its earnings results on Wednesday, March 5th. The company reported ($1.01) earnings per share for the quarter, beating the consensus estimate of ($1.14) by $0.13.

Institutional Investors Weigh In On iTeos Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the company. BVF Inc. IL acquired a new position in iTeos Therapeutics in the fourth quarter valued at $17,856,000. JPMorgan Chase & Co. raised its position in iTeos Therapeutics by 342.7% in the fourth quarter. JPMorgan Chase & Co. now owns 2,068,796 shares of the company’s stock valued at $15,888,000 after purchasing an additional 1,601,477 shares during the period. Boxer Capital Management LLC acquired a new position in iTeos Therapeutics during the 4th quarter worth approximately $7,272,000. Jacobs Levy Equity Management Inc. lifted its position in shares of iTeos Therapeutics by 347.9% during the fourth quarter. Jacobs Levy Equity Management Inc. now owns 922,134 shares of the company’s stock worth $7,082,000 after purchasing an additional 716,271 shares in the last quarter. Finally, Millennium Management LLC lifted its holdings in iTeos Therapeutics by 1,008.8% in the 4th quarter. Millennium Management LLC now owns 411,072 shares of the company’s stock worth $3,157,000 after buying an additional 373,999 shares in the last quarter. 97.16% of the stock is currently owned by hedge funds and other institutional investors.

About iTeos Therapeutics

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.